HOME >> MEDICINE >> NEWS
Jefferson scientists create first animal model of common type of leukemia

Researchers at Jefferson Medical College and the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia have developed the first animal model of the most common type of human leukemia. The new model should enable scientists to gain both a better understanding of the biochemical and molecular mechanisms underlying the disease, chronic lymphocytic leukemia (CLL), while at the same time provide a testing ground for potential new drugs.

"This is a very important discovery because now we have an animal model to use to develop and test new drugs," says Carlo Croce, M.D., professor and chair of microbiology and immunology at Jefferson Medical College of Thomas Jefferson University and director of the Kimmel Cancer Center, who led the work. "The model indicates what initiates the malignancy and provides us with interesting new targets involved in the earliest steps in the disease."

Several years ago, Dr. Croce and his co-workers isolated a gene, TCL-1, located on chromosome 14, and implicated it in several types of human leukemias and lymphomas, such as T-cell CLL and adult T-cell leukemia. These cancers are characterized by chromosomal rearrangements and in turn the uncontrolled proliferation of T-cells, key infection fighting white blood cells. According to Dr. Croce, TCL-1 is also expressed in two other types of cancer: B-cell CLL and B-cell lymphoma.

"We were puzzled by the fact that all B-cell CLL expressed TCL-1," Dr. Croce explains. "Cytogenetically B-cell CLL and B-cell lymphoma do not show the translocations or rearrangements of the TCL-1 gene observed in T-cell tumors." To better understand why, Dr. Croce and his co-workers created transgenic mice in which TCL-1 essentially is put into overdrive in B-cells.

Surprisingly, they found that when the gene is hyperactive, it produces too much of its protein product, resulting in uncontrolled expansion of leukemic cells and a disease identical to human B-cell CLL. "We did not predi
'"/>

Contact: Steve Benowitz
steven.benowitz@mail.tju.edu
215-955-5291
Thomas Jefferson University
21-May-2002


Page: 1 2

Related medicine news :

1. Jefferson Lab medical imager spots breast cancer
2. Jefferson scientists uncover potential trigger of diabetic kidney disease
3. Uric acid may help reduce effects of spinal cord injury, Jefferson researchers find
4. Jefferson scientists help explain statins effects in Alzheimers disease
5. Jefferson scientists find zinc may help prevent esophageal, oral cancers
6. Jefferson virologists coax HIV out of hiding
7. Jefferson scientists find way to see breast cancer activity from outside the body
8. Jefferson and Molecular Targeting Technologies, Inc. scientists create vaccine for wildlife rabies
9. Jefferson scientists use gene therapy to rescue failing hearts in animals
10. Jefferson scientists reveal how some types of rabies invade the brain
11. Jefferson neuroscientists studying new type of Alzheimers drug to halt disease progression

Post Your Comments:
(Date:8/28/2014)... 2014 Kirklyn Smith, an office manager for ... a new world’s record by walking 5,000 miles in a ... constantly amazed by the thousands of individual stories of TrekDesk ... to stand out more than the others. , Kirklyn has ... count which tallies a range of 54,823 steps (presumably on ...
(Date:8/28/2014)... (HealthDay News) -- Lack of sleep not only puts teens ... increased risk for obesity, researchers warn. The study authors ... were aged 16 and 21. Nearly one-fifth of them got ... were age 16, and this group was 20 percent more ... got more than eight hours of sleep per night at ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 NJ ... Institute of North Jersey. , NJ Top Doc, ... is now a certified medical examiner for the ... certified by the department to perform all drug ... training in diagnosing and treating musculoskeletal disorders including ...
(Date:8/28/2014)... In 2012, The Ben & Catherine Ivy Foundation ... brain cancer research projects at the Translational Genomics ... officially received the final regulatory approval from University ... for the trial can begin. , In the ... Trial," TGen and its clinical partners will lead ...
(Date:8/28/2014)... August 28, 2014 As Mirena IUD ... around the U.S., Bernstein Liebhard LLP notes that a ... like Mirena as ideal birth control for teenage girls. ... authors of the study point out that IUDs are ... other methods favored by this patient population. Their study, ...
Breaking Medicine News(10 mins):Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:Less Sleep in Teen Years Tied to More Pounds at 21 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 3Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 3Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 4
(Date:8/28/2014)... Aug. 28, 2014  In recognition of the increased ... from the flu, pneumonia, shingles and other illnesses, ... declared September to be Senior Vaccination Month. Because ... is important that adults ages 65 years and ... CVS pharmacists and MinuteClinic nurse practitioners and physician ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... Therapeutics in Asia-Pacific Markets to 2020 ... Unmet Need in Newly Diagnosed and ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html Glioblastoma ...
(Date:8/28/2014)... , Aug. 28, 2014 Telik, Inc. ... company that merged with MabVax Therapeutics, Inc. on ... significant progress related to the development of its ... was recovered using the Company,s internally developed antibody ... potential for multiple antibody based therapeutic and diagnostic ...
Breaking Medicine Technology:September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4
Cached News: